In this study, DAYVIGO therapy significantly improved both sleep onset and sleep maintenance compared with placebo.
'We are pleased to share these important study results in JAMA Network Open,' said
SUNRISE 1 was a global, randomized, double-blind, placebo-controlled, active comparator parallel-group study of 1,006 adults 55 years of age or older with insomnia disorder receiving DAYVIGO 5 mg or 10 mg, an active comparator or placebo for one month at bedtime. The primary study endpoint was the change from baseline in latency to persistent sleep for DAYVIGO therapy versus placebo. Key secondary endpoints were changes from baseline in sleep efficiency and wake after sleep onset compared with placebo, and wake after sleep onset in the second half of the night compared with the active comparator. Treatment-emergent adverse events reported in 2% of participants in any active treatment group included headache (6.2% for placebo, 5.3% for active comparator, 6.4% for DAYVIGO 5 mg, and 4.9% for DAYVIGO 10 mg) and somnolence (1.9% for placebo, 1.5% for active comparator, 4.1% for DAYVIGO 5 mg, and 7.1% for DAYVIGO 10 mg). Full study results can be accessed in the JAMA Network Open publication.
DAYVIGO was approved by the
JAMA Network Open is an international, peer-reviewed, open access, general medical journal, and is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.
About Lemborexant
Lemborexant is a small-molecule compound, discovered and developed by
About Sleep Disorders
Population studies show that sleep disorders affect many more people worldwide than previously thought.3 Insomnia symptoms affect approximately 30% of the adult population worldwide.4 Insomnia disorder is characterized by difficulty falling asleep, staying asleep or both, despite an adequate opportunity to sleep, which can lead to daytime consequences, such as fatigue, difficulty concentrating, and irritability.5,6
Sleeping well is essential for good health, including brain health. Poor sleep is associated with a wide range of health consequences.5
Experimental studies in animals and humans provide evidence of associations between sleep and disease risk factors, diseases, and mortality.7 Studies suggest an optimal sleep duration between seven and eight hours.8
Women are 1.4 times more likely than men to suffer from insomnia.9 Older adults also have higher prevalence of insomnia; aging is often accompanied by changes in sleep patterns, including disrupted sleep, frequent waking, and early waking, that can lead to less sleep time.10
About
At
Contact:
Tel: 551-502-2710
Email: JamesMerse@eisai.com
(C) 2019 Electronic News Publishing, source